{
    "clinical_study": {
        "@rank": "156491", 
        "acronym": "PR1C", 
        "arm_group": [
            {
                "arm_group_label": "10mg MD", 
                "arm_group_type": "Experimental", 
                "description": "APD791 10mg Multiple dose and"
            }, 
            {
                "arm_group_label": "20mg MD", 
                "arm_group_type": "Experimental", 
                "description": "APD791 20mg Multiple dose"
            }, 
            {
                "arm_group_label": "40mg MD", 
                "arm_group_type": "Experimental", 
                "description": "APD791 40mg Multiple dose"
            }, 
            {
                "arm_group_label": "60mg MD", 
                "arm_group_type": "Experimental", 
                "description": "APD791 60mg Multiple dose"
            }, 
            {
                "arm_group_label": "Placebo MD", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo for Multiple dose group"
            }, 
            {
                "arm_group_label": "120mg SD", 
                "arm_group_type": "Experimental", 
                "description": "APD791 120mg Single dose"
            }, 
            {
                "arm_group_label": "240mg SD", 
                "arm_group_type": "Experimental", 
                "description": "APD791 240mg Single dose"
            }, 
            {
                "arm_group_label": "320mg SD", 
                "arm_group_type": "Experimental", 
                "description": "APD791 320mg Single dose"
            }, 
            {
                "arm_group_label": "Placebo SD", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo for Single dose"
            }
        ], 
        "brief_summary": {
            "textblock": "Evaluating safety and PK parameter of APD-791 when co-administered with aspirin and\n      clopidogrel."
        }, 
        "brief_title": "Safety Study of APD-791 With Aspirin and/or Clopidogrel", 
        "condition": "Acute Coronary Syndrome", 
        "condition_browse": {
            "mesh_term": "Acute Coronary Syndrome"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. a healthy adult between 20 and 45 years old at the time of visit for screening\n\n          2. a person who is able to give written consent\n\n          3. a person between 50 and 85 kg at the time of visit for screening\n\n          4. a woman who is negative on a serum hCG test at the time of visit and the day before a\n             trial, and who is not nursing\n\n          5. a woman who agrees on double contraception, medically approved, from the time of\n             visit for screening to 90 days after the last administration of a clinical trial\n             drug, or who had a contraceptive operation no later than 120 days before visit for\n             screening, or who is menopausal\n\n          6. a man who had a contraceptive operation no later than 120 days before visit for\n             screening, or who agrees on double contraception, medically approved, from the time\n             of visit for screening to 90 days after the last administration of a clinical trial\n             drug, and also agree not to donate sperm\n\n          7. a person more than hemoglobin 12 g/dL at the time of screening (a woman more than\n             hemoglobin 11 g/dL)\n\n          8. a person whose vital signs were in the normal range at the time of visit for\n             screening, or who is medically determined not to be clinically significant by an\n             investigator\n\n          9. a person who voluntarily decides to participate in this clinical trial and gives\n             written consent on strict clinical trial compliance\n\n         10. a person whose blood can be collected during a study period with visit for monitoring\n\n        Exclusion Criteria:\n\n          1. a person with the medical history of gastric ulcer, duodenal ulcer or esophageal\n             ulcer within 90 days from the time of visit for screening\n\n          2. a person with the medical history of gastrointestinal diseases(e.g. Crohn's disease,\n             ulcerative colitis, etc.) or surgery(excluding uncomplicated appendectomy or\n             herniotomy) affecting the absorption of a clinical trial drug\n\n          3. a person with the medical history of blood coagulation disorder or hemorrhagic\n             diseases, or with clinically significant abnormal findings decided by a investigator\n             on blood coagulation test at the time of screening\n\n          4. a woman with the medical history of dysfunctional uterine bleeding within a year from\n             the time of visit for screening\n\n          5. a person with the medical history of epilepsy or convulsion\n\n          6. a person with the medical history of internal organ transplant\n\n          7. a person expected to be hard to complete a clinical trial because of surgery or\n             medical procedures planned within a clinical trial period\n\n          8. a person with the medical history of clinically significant new diseases within 30\n             days from the time of visit for screening according to investigator's decision\n\n          9. a person with hypersensitivity reaction to a drug or gelatin, or the medical history\n             of clinically significant hypersensitivity reaction\n\n         10. a person with the history of drug abuse, or with a positive reaction to a drug\n             possible to be abused on urine drug screening\n\n         11. a person with the medical history of alcohol abuse within two years from the time of\n             visit for screening\n\n         12. a person who is a smoker, or with a positive reaction on a urine nicotine test\n             conducted at the time of visit for screening\n\n         13. a person who donated whole blood within 60 days or constituents of blood within 30\n             days, or received a blood transfusion within 30 days from the time of visit for\n             screening\n\n         14. a person taking other clinical trial drugs within 90 days from the time of visit for\n             screening\n\n         15. a person taking a prescription drug within 30 days, or a contraindicated drug or\n             oriental medicine within 14 days from the time of visit for screening\n\n         16. a person with a positive reaction to a serum test(hepatitis B test, hepatitis C test,\n             HIV test, syphilis test)\n\n         17. a person with hepatic enzymes(AST, ALT) more than 2.5 times of the reference upper\n             limit(UNL) or total bilirubin more than 1.5 times of the reference upper limit(UNL)\n             or creatinine more than 1.25 times of the reference upper limit(UNL)\n\n         18. a person expected to be hard to complete a clinical trial due to physical or mental\n             status according to investigator's medical decision at the time of visit for\n             screening\n\n         19. a person decided to be inappropriate to participate in this clinical trial according\n             to investigator's medical decision on the result of laboratory tests, such as\n             complete blood cell count, general chemical test, clinicochemical urinalysis, and\n             physical examination, vital signs, ECG, other tests excluding exclusion criteria 17\n             items conducted before subject selection for a clinical trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "88", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02034292", 
            "org_study_id": "ID-PR1C-1301"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "10mg MD", 
                    "20mg MD", 
                    "40mg MD", 
                    "60mg MD", 
                    "Placebo MD", 
                    "120mg SD", 
                    "240mg SD", 
                    "320mg SD", 
                    "Placebo SD"
                ], 
                "intervention_name": "Clopidogrel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "10mg MD", 
                    "20mg MD", 
                    "40mg MD", 
                    "60mg MD", 
                    "Placebo MD", 
                    "120mg SD", 
                    "240mg SD", 
                    "320mg SD", 
                    "Placebo SD"
                ], 
                "intervention_name": "Aspirin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "10mg MD", 
                    "20mg MD", 
                    "40mg MD", 
                    "60mg MD", 
                    "Placebo MD", 
                    "120mg SD", 
                    "240mg SD", 
                    "320mg SD"
                ], 
                "intervention_name": "APD791", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo SD", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Aspirin", 
                "Clopidogrel", 
                "Pamidronate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 10, 2014", 
        "number_of_arms": "9", 
        "official_title": "Phase I Study to Assess the Safety of APD-791 When Co-administered With Aspirin", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Adverse reaction monitoring for subjective or objective symptoms Physical examination Vital signs 12-electrode ECG Laboratory tests", 
            "measure": "To assess the safety of APD791 when orally co-administered with Aspirin and Clopidogrel in healthy subjects", 
            "safety_issue": "Yes", 
            "time_frame": "safety review will be conducted at every end of dosing (about every 2 or 3 weeks)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02034292"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Non-compartmental analysis is conducted by using APD791 and its metabolite, M1 and M2 and the following pharmacokinetic evaluation variables are calculated.\nCmax0-12, Cmax,ss (Day 7 only), Cmin,ss (Day 7 only), tmax0-12, tmax,ss (Day 7 only), \u03bbz, t1/2\u03b2, AUC0-12 (Day 1 only), AUCinf, Accumulation index, CL/F, MRT, Vz/F", 
                "measure": "Pharmacokinetic characteristic evaluation variable", 
                "safety_issue": "No", 
                "time_frame": "After last patient last visit. About 8month later since start of the study."
            }, 
            {
                "description": "Pharmacodynam1) % inhibition of serotonin-stimulated platelet aggregation 2) Change in % inhibition of serotonin-stimulated platelet aggregation 3) % inhibition of TRAP-induced platelet aggregation ic characteristic evaluation variable", 
                "measure": "Pharmacodynamic characteristic evaluation variable", 
                "safety_issue": "No", 
                "time_frame": "Day1, Day4, Day7 of every dose for mutiple dose group and first day for single dose group."
            }
        ], 
        "source": "IlDong Pharmaceutical Co Ltd", 
        "sponsors": {
            "collaborator": {
                "agency": "Asan Medical Center", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "IlDong Pharmaceutical Co Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}